https://pubmed.ncbi.nlm.nih.gov/29615901/
Sunitinib is the most commonly prescribed drug for advanced renal cell carcinoma in the first-line setting and has been associated with multiple adverse events...
adjunct therapykidney cancerisoquercetinpatients